Sonia Razzetti - Disc Medicine Senior Quality
| IRON Stock | 80.65 3.33 4.31% |
Executive
Sonia Razzetti is Senior Quality of Disc Medicine
| Address | 321 Arsenal Street, Watertown, MA, United States, 02472 |
| Phone | 617 674 9274 |
| Web | https://www.discmedicine.com |
Disc Medicine Management Efficiency
The company has return on total asset (ROA) of (0.2261) % which means that it has lost $0.2261 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3478) %, meaning that it created substantial loss on money invested by shareholders. Disc Medicine's management efficiency ratios could be used to measure how well Disc Medicine manages its routine affairs as well as how well it operates its assets and liabilities. As of the 3rd of February 2026, Return On Tangible Assets is likely to drop to -0.21. In addition to that, Return On Capital Employed is likely to grow to -0.3. At this time, Disc Medicine's Total Assets are very stable compared to the past year. As of the 3rd of February 2026, Other Assets is likely to grow to about 217.3 K, while Net Tangible Assets are likely to drop (60.7 M).Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Zhichao Si | Ascentage Pharma Group | N/A | |
| Chongdong Fu | Ascentage Pharma Group | N/A | |
| Doug Wallace | Legend Biotech Corp | N/A | |
| Vijay MD | CG Oncology Common | 58 | |
| Dan Mulreany | Apogee Therapeutics Common | N/A | |
| MSc MD | Apogee Therapeutics Common | N/A | |
| Aziz MBA | Tarsus Pharmaceuticals | 48 | |
| Adrienne Kemp | Tarsus Pharmaceuticals | N/A | |
| MBA III | Celcuity LLC | 65 | |
| Shan He | Zai Lab | N/A | |
| Andrea JD | Xenon Pharmaceuticals | 58 | |
| Carlos Santos | Legend Biotech Corp | N/A | |
| Edward MBA | Scholar Rock Holding | 53 | |
| Steven Gavel | Legend Biotech Corp | N/A | |
| MD JD | Tarsus Pharmaceuticals | 48 | |
| Jessie MBA | Legend Biotech Corp | 41 | |
| Tina Carter | Legend Biotech Corp | N/A | |
| Charmayne Chan | Ascentage Pharma Group | 41 | |
| Matthew MBA | Tarsus Pharmaceuticals | 48 | |
| Matthew JD | Apogee Therapeutics Common | 50 | |
| Yajing Chen | Zai Lab | 58 | |
Management Performance
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.23 |
Disc Medicine Leadership Team
Elected by the shareholders, the Disc Medicine's board of directors comprises two types of representatives: Disc Medicine inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Disc. The board's role is to monitor Disc Medicine's management team and ensure that shareholders' interests are well served. Disc Medicine's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Disc Medicine's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jonathan Yu, Chief Officer | ||
| Rahul Kaushik, Chief Officer | ||
| Donald Nicholson, Independent Chairman | ||
| Sonia Razzetti, Senior Quality | ||
| Joanne CPA, Chief Officer | ||
| William MD, Chief Officer | ||
| Pamela MPH, Chief Officer | ||
| Jean CPA, Chief Officer | ||
| Hua Yang, Senior Pharmacology | ||
| Lisa Price, Chief Officer | ||
| Jean Franchi, Chief Officer | ||
| Srikanth Venkatraman, Senior Chemistry | ||
| Esq JD, President CEO | ||
| Jonathan MBA, Chief Officer | ||
| Melanie Chin, VP Affairs | ||
| Min Wu, Vice Innovation | ||
| ChB MB, Founder Board | ||
| Steven MD, Chief Officer | ||
| PharmD JD, Compliance Counsel |
Disc Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Disc Medicine a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.23 | ||||
| Current Valuation | 2.38 B | ||||
| Shares Outstanding | 37.75 M | ||||
| Shares Owned By Insiders | 7.79 % | ||||
| Shares Owned By Institutions | 99.38 % | ||||
| Number Of Shares Shorted | 4.28 M | ||||
| Price To Book | 5.09 X | ||||
| EBITDA | (108.27 M) | ||||
| Net Income | (109.36 M) |
Pair Trading with Disc Medicine
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Disc Medicine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Disc Medicine will appreciate offsetting losses from the drop in the long position's value.Moving together with Disc Stock
Moving against Disc Stock
| 0.8 | VYNE | Vyne Therapeutics | PairCorr |
| 0.68 | FBIO | Fortress Biotech | PairCorr |
| 0.58 | KPTI | Karyopharm Therapeutics | PairCorr |
| 0.53 | KOD | Kodiak Sciences | PairCorr |
| 0.48 | VRTX | Vertex Pharmaceuticals Earnings Call Tomorrow | PairCorr |
The ability to find closely correlated positions to Disc Medicine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Disc Medicine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Disc Medicine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Disc Medicine to buy it.
The correlation of Disc Medicine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Disc Medicine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Disc Medicine moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Disc Medicine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Disc Medicine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Disc Stock, please use our How to Invest in Disc Medicine guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Will Biotechnology sector continue expanding? Could Disc diversify its offerings? Factors like these will boost the valuation of Disc Medicine. Market participants price Disc higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Disc Medicine data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate Disc Medicine using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Disc Medicine's intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Disc Medicine's market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Disc Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Disc Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Disc Medicine's market price signifies the transaction level at which participants voluntarily complete trades.